BioRestorative Therapies reports potential licensing discussions for its ThermoStem® metabolic IP with an unnamed regenerative medicine firm.
BioRestorative Therapies, a clinical-stage stem cell company, reports potential licensing discussions with an undisclosed commercial-stage regenerative medicine firm for its allogeneic ThermoStem® metabolic IP. The platform uses brown adipose derived stem cells to treat obesity and metabolic disorders, with preclinical results showing promising effects. No assurances about a licensing agreement are given.
June 13, 2024
3 Articles